Sacituzumab tirumotecan: all 95 studies that test it

Page 1 of 1. Open to participants first (79), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI FailureNot yet recruitingNCT07854509Phase 2
• A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract CancerRecruitingNCT07850791Phase 2
• A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)Not yet recruitingNCT07829783Phase 3
• Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07823270Phase 2
• Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07819578Phase 2
• Sacituzumab Tirumotecan as Second-Line Treatment for Penile CancerNot yet recruitingNCT07815197Phase 2
• Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal CancerRecruitingNCT07811752Phase 2
• Sac-TMT in Vaginal and Vulvar CancersNot yet recruitingNCT07804966Phase 2
• Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain MetsNot yet recruitingNCT07789444Phase 2
• A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)RecruitingNCT07785609Phase 2
• Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNot yet recruitingNCT07750704Phase 2
• A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic CarcinomasNot yet recruitingNCT07750353Phase 2
• SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological MalignanciesNot yet recruitingNCT07738757Phase 2
• Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination TherapyNot yet recruitingNCT07720258Phase 2
• Genitourinary Tumors With Sacituzumab TirumotecanNot yet recruitingNCT07716917Phase 2
• Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung CancerNot yet recruitingNCT07702305Phase 1
• Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Phase 2
• Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract CancerNot yet recruitingNCT07701122Phase 2
• SKB264 in Combination With SKB118 for Non-Small Cell Lung CancerRecruitingNCT07697586Phase 2
• Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07689292Phase 2
• Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07686588Phase 2
• SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II StudyRecruitingNCT07670013Phase 2
• Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)Not yet recruitingNCT07662863Phase 2
• Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior ChemotherapyNot yet recruitingNCT07639086Phase 2
• Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA MutationsNot yet recruitingNCT07628504Phase 3
• Sac-TMT Combined With Bevacizumab in TNBC With Brain MetastasesRecruitingNCT07623577Phase 2
• SKB118 Injection in Advanced Solid TumorsRecruitingNCT07586943Phase 1/2
• Sacituzumab Tirumotecan for Pancreatic CancerNot yet recruitingNCT07561463Phase 2
• A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based ChemotherapyRecruitingNCT07548060Phase 2
• Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver MetastasisNot yet recruitingNCT07545213Phase 2
• Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)Not yet recruitingNCT07521670Phase 2
• Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/RectumNot yet recruitingNCT07511023Phase 2
• Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Not yet recruitingNCT07501169Phase 2
• Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingNCT07466927Phase 2
• Sac-TMT for Active TNBC Brain MetastasesNot yet recruitingNCT07458113Phase 2
• Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary CarcinomaRecruitingNCT07438626Phase 2
• A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingNCT07419295Phase 3
• Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLCNot yet recruitingNCT07388875Phase 2
• A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib MonotherapyRecruitingNCT07375316Phase 2
• Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast CancerRecruitingNCT07371208Phase 2
• A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical CancerNot yet recruitingNCT07348861Phase 2
• A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial TumorsNot yet recruitingNCT07343453Phase 2
• Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2
• Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaRecruitingNCT07324629Phase 2
• Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung CancerRecruitingNCT07323056Phase 2
• A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)RecruitingNCT07318558Phase 3
• SKB264 Plus QL1706 in Recurrent or Metastatic Cervical CancerRecruitingNCT07256236Phase 2
• Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung CancerNot yet recruitingNCT07244926Phase 2
• Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBCNot yet recruitingNCT07244874Phase 2
• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RecruitingNCT07216703Phase 3
• Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain MetastasisNot yet recruitingNCT07197008Phase 2
• Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNot yet recruitingNCT07193160Phase 2
• SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd TreatmentRecruitingNCT07182721Phase 2
• Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)RecruitingNCT07179783Phase 2
• Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast CancerNot yet recruitingNCT07153965Phase 2
• Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast CancerNot yet recruitingNCT07139470Phase 1/2
• SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerNot yet recruitingNCT07109284Phase 2
• Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCRecruitingNCT07088211Phase 2
• The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard TherapyNot yet recruitingNCT07077564Phase 2
• A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyRecruitingNCT07071337Phase 3
• Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerRecruitingNCT07068542Not applicable
• A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)Not yet recruitingNCT07054242Phase 2
• Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBCNot yet recruitingNCT07007780Phase 2
• Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06992739Phase 2
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Phase 3
• A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingNCT06952504Phase 3
• HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNot yet recruitingNCT06849492Phase 2
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingNCT06841354Phase 3
• A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)RecruitingNCT06824467Phase 3
• Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLCNot yet recruitingNCT06706219Phase 2
• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)RecruitingNCT06637423Phase 1/2
• Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingNCT06445972Phase 1/2
• Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Phase 3
• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)RecruitingNCT06393374Phase 3
• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingNCT06312176Phase 3
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingNCT06312137Phase 3
• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Phase 3
• Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerRecruitingNCT06081959Phase 3
• A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2
• Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLCActive, not recruitingNCT07703228Phase 2
• Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OCActive, not recruitingNCT07341100Phase 2
• A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Phase 3
• A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06670196Phase 3
• A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)Active, not recruitingNCT06459180Phase 3
• A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Phase 3
• A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Phase 3
• Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active, not recruitingNCT06305754Phase 3
• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06279364Phase 3
• Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)Active, not recruitingNCT06132958Phase 3
• Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active, not recruitingNCT06074588Phase 3
• A Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsActive, not recruitingNCT05870319Phase 3
• SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid TumorsActive, not recruitingNCT05642780Phase 2
• SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsActive, not recruitingNCT05631262Phase 2
• SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerActive, not recruitingNCT05347134Phase 3
• Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Phase 1/2

← Sacituzumab tirumotecan overview